title: Pentoxifylline Treatment of Very Low Birth Weight Neonates with Nosocomial Sepsis.
abstract: ObjectiveThe objective of this study was to assess the result of intravenous pentoxifylline as an adjunct to antibiotic therapy on mortality and morbidity in very low birth weight (VLBW) preterm neonates with nosocomial sepsis.MethodsFor the 18 VLBW preterm neonates, as an adjunct therapy to antibiotics regimens, pentoxifylline (5 mg/kg/h for 6 hours) was administered to premature infants with sepsis on 3 successive days. Clinical and laboratory parameters were recorded before and after treatment.ResultsFollowing pentoxifylline therapy, the immature-to-total neutrophil ratio and C-reactive protein (CRP) levels were significantly decreased, while the blood pH and base excess were significantly increased (p< 0.05). The axillary temperature, noninvasive blood pressure, hemoglobin, leukocyte, and thrombocyte values did not significantly differ after treatment (p> 0.05). Coagulase-negative staphylococci (CoNS) (32%),Streptococcus hominis(7.3%),Pseudomonas aeruginosa(5.3%), andCandida parapsilosis(3.1%) were identified in the blood cultures. There were no short-term morbidities (intraventricular hemorrhages, necrotizing enterocolitis, periventricular leukomalacia, and patent ductus arteriosus), no adverse effects, and no mortalities during or after the pentoxifylline therapy in the preterm neonate participants.ConclusionThe CRP levels and heart rate both decreased, while the pH and base excess parameters of the blood gas analysis changed positively after pentoxifylline treatment in VLBW preterm neonates with nosocomial sepsis.
authors.affiliation: Department of Pediatrics, Bagcılar Training and Research Hospital, Istanbul, Turkey.
authors.forename: Şahin
authors.initials: Ş
authors.lastname: Hamilçıkan
authors.affiliation: Department of Pediatrics, Bagcılar Training and Research Hospital, Istanbul, Turkey.
authors.forename: Emrah
authors.initials: E
authors.lastname: Can
authors.affiliation: Department of Pediatrics, Bagcılar Training and Research Hospital, Istanbul, Turkey.
authors.forename: Övgü
authors.initials: Ö
authors.lastname: Büke
authors.affiliation: Department of Pediatrics, Bagcılar Training and Research Hospital, Istanbul, Turkey.
authors.forename: Meltem
authors.initials: M
authors.lastname: Erol
authors.affiliation: Department of Pediatrics, Bagcılar Training and Research Hospital, Istanbul, Turkey.
authors.forename: Özlem Bostan
authors.initials: ÖB
authors.lastname: Gayret
mesh_terms: D061605:Administration, Intravenous; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001419:Bacteria / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D001431:Bacteriological Techniques / Q000379:methods; D003428:Cross Infection / Q000150:complications / Q000382:microbiology; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000453:epidemiology; D019102:Infant, Very Low Birth Weight; D008297:Male; D000071074:Neonatal Sepsis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000401:mortality; D010431:Pentoxifylline / Q000008:administration & dosage / Q000009:adverse effects; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014421:Turkey / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents; D010726:Phosphodiesterase Inhibitors; D010431:Pentoxifylline